Krissy Vann | Host, All Things Fitness and Wellness
Oura is moving further into clinical healthcare, launching its first clinical trial with UC San Diego Health to investigate how wearable data could help researchers understand patient outcomes following GLP-1 treatment and bariatric surgery.
The multi-year study, called SMART-BMI, will examine whether changes in sleep, heart rate and physical activity are associated with weight loss, blood sugar control and treatment persistence. The research will focus on what happens between medical appointments, when changes in patients' daily health and behaviour can be difficult to capture through conventional clinical monitoring.
The study comes as GLP-1 medications reshape obesity treatment and raise new questions about how patients respond to these therapies over time. Researchers will investigate whether continuous physiological monitoring can provide additional information about treatment outcomes, although the study has not yet established whether wearable data can improve clinical decision-making.
The trial is registered at ClinicalTrials.gov under NCT07736729.
Oura's entry into clinical trials also marks a shift in how the smart ring manufacturer is approaching healthcare. The company has spent the past year formalizing its Office of Regulatory and Clinical Affairs (ORCA), led by Chief Medical Officer Dr. Ricky Bloomfield, to oversee clinical research, regulatory compliance and the evaluation of health outcomes.
"Since I started at Oura, my focus has been on formalizing the clinical rigor behind the trust people already place in their ring," said Bloomfield.
Oura says its technology has been included in more than 200 peer-reviewed publications covering sleep, cardiovascular health, metabolic health, women's health and other areas. The company is now extending that research into studies examining whether continuous biometric data can help researchers understand patient outcomes and healthcare utilization.
Beyond obesity treatment, Oura is working with Maven Clinic on a study examining fertility tracking and pregnancy outcomes involving at least 5,000 participants. A separate collaboration with Johns Hopkins School of Medicine will monitor patients for up to 12 months following hospitalization for acute kidney injury.
Other researchers are investigating potential applications of Oura data in heart failure, depression and inflammatory arthritis. Mount Sinai Doctors–Concierge Care is also incorporating Oura Ring 5 data into its Healthspan Membership program to give physicians access to biometric trends between appointments.
The developments reflect a growing interest in moving consumer wearable technology beyond fitness and wellness tracking into clinical research and patient monitoring. However, establishing the accuracy of individual measurements is different from demonstrating that those measurements can improve medical outcomes.
For Oura, the SMART-BMI trial represents an opportunity to investigate that distinction in one of healthcare's rapidly evolving treatment categories.
The company has not announced when the trial is expected to conclude or when findings will be published.
